No abstract available.
P-Glycoprotein* ; Stomach Neoplasms*

No abstract available.
Breast* ; DNA* ; P-Glycoprotein*

Extranodal NK/T-cell lymphoma (ENKL) is a rare subtype of NHL (Non-Hodgkin lymphoma]. It occurs mostly in the nasal and paranal areas. Most of the cases are presented stage I/II. International prognostic index (IPI) can predict the outcome. However, better prognostic model is available such as NKIPI. Because of high expression of p-glycoprotein, ENKL is refractory to chemotherapy. Early stage disease can be bestly treated with concurrent chemoradiation. For advanced stage disease, new clinical trials are now being conducted.
Lymphoma ; P-Glycoprotein

No abstract available.
Leukemia, Monocytic, Acute* ; P-Glycoprotein*

No abstract available.
Carcinoma, Transitional Cell* ; Humans* ; P-Glycoprotein* ; Urinary Bladder*

Oseltamivir is a substrate of P-glycoprotein, an efflux drug transporter encoded by ABCB1. The objective of this study was to assess the role of ABCB1 (c.1236C>T, c.2677G>T/A, and c.3435C>T) polymorphisms in the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate in humans. Nineteen healthy male subjects were enrolled, and their ABCB1 polymorphisms were evaluated. After the oral administration of 75 mg oseltamivir, the plasma concentrations of oseltamivir and oseltamivir carboxylate were measured. Pharmacokinetic analysis was carried out. Systemic exposure to oseltamivir and oseltamivir carboxylate was higher in the mutant group than in the wild-type and heterozygous groups. We suggest that ABCB1 polymorphisms affect the pharmacokinetics of oseltamivir in humans. Further studies in a large population are necessary to validate the results of this preliminary study (Clinical Trial Registration Information [CRIS] registry: http://cris.nih.go.kr, No. KCT0001903).
Administration, Oral ; Humans* ; Male ; Oseltamivir* ; P-Glycoprotein ; Pharmacokinetics* ; Plasma

OBJECTIVE: We determined the influence of 3-OMD in the protein binding of levodopa to estimate the effect of 3-OMD on the penetration of levodopa into brain. METHOD: P-glycoprotein in the brain may serve to limit drug penetration into the brain. Because it is not available as an experimental substance, but has similar binding properties with alpha 1 acid glycoprotein(AGP), we used AGP in this study. Additionally, we used blood plasma to see the affinity of plasma binding of levodopa. The final concentration of chemicals used in this study were 125, 250, 500, 1000, 2000, 4000 microgram/l for levodopa and 0, 1250, 5000, 10,000 microgram/l for 3-OMD, 1 mg/l for AGP. The free fraction of levodopa in blood plasma and AGP were separated by ultrafiltration method and determined by beta-counter, respectively. RESULTS: We found that levodopa did not bind with AGP, but only 22-24% from 125 microgram/l to 4000 microgram/l of it bound with blood plasma. The addition of 3-OMD to the blood plasma did not significantly change the binding of levodopa. CONCLUSIONS: We can conclude that 3-OMD does not influence the penetration of levodopa into brain. These small amount of the binding does not expect to influence to other drugs on the binding with plasma.
Brain ; Drug Interactions ; Levodopa* ; P-Glycoprotein ; Plasma* ; Protein Binding ; Ultrafiltration

PURPOSE: We wanted to determine the prognostic significance of P-glycoprotein (Pgp) and multi drug resistance-assdegrees Ciated protein (MRP) in stage III gastric adendegrees Carcinoma by evaluating whe ther the Pgp and/or MRP expression correlate with various clinicopathological parameters and survival rates. MATERIAL AND METHODS: The expression of Pgp and/or MRP were studied immunohistdegrees Chemi cally by ABC method with paraffin-embedded tissue specimens which were surgically obtained from 64 cases of stage III gastric adendegrees Carcinomas at the Department of Surgery, Presbyterian Medical Center from 1991 to 1992. Statistical differences of both expression in various factors including survival rates and clinicopatholgical parameters were sought. RESULTS: Expression rates of Pgp and MRP group were 50.0% and 43.7% respectively. There was no significant correlation between expression of two proteins and various clinicopathological variables such as age, sex, stage, tumor depth, number of metastatic node, tumor size, site and method of operation. However, in case of the degree of differenciation, the expression of Pgp and/or MRP was significantly greater in well differenciated adendegrees Carcinoma than in poorly dif ferenciated adendegrees Carcinoma (p=0.001, p=0.012). Statistically, no significant correlations between the expression of Pgp and/or MRP and overall survival rates were found. CONCLUSION: These results suggest that the Pgp and/or MRP expression in patients with stage III gastric adendegrees Carcinomas are not useful in determining postoperative chemotherapy and as an independent predictor of survival.
Drug Resistance, Multiple* ; Drug Therapy ; Humans ; P-Glycoprotein ; Protestantism ; Stomach Neoplasms ; Survival Rate

OBJECTIVES: The purpose of this study was to evaluate expression of cyclooxygenase-2 (COX-2) and P-glycoprotein (P-gp) in ovarian epithelial carcinomas, to find out the correlations between their expression and clinicopathological parameters, and to evaluate the response to treatment and clinical outcome according to their expression. METHODS: Immunohistochemical studies of COX-2 and P-gp were carried out in 64 cases that were treated with ovarian epithelial carcinomas at Department of Obstetrics and Gynecology, Korea University Hospital, Korea University from 1996 to 2005. RESULTS: COX-2 over-expression was detected in 20 (31.2%) cases and was significantly higher in non-responder than responder to chemotherapy (56.2% versus 22.9%, respectively; P=0.012). The patients of COX-2 overexpression showed shorter overall survival (P<0.001). Over-expression of P-gp was detected in 15 (23.4%) cases was significantly higher in non-responder than responder to chemotherapy (56.2% versus 12.5%, respectively; P<0.001). The patients of P-gp overexpression showed shorter overall survival (P= 0.042). CONCLUSION: COX-2 and P-gp overexpression could provide additional information to identify ovarian carcinoma patients with poor chance of response to chemotherapy.
Cyclooxygenase 2* ; Drug Therapy ; Gynecology ; Humans ; Korea ; Obstetrics ; P-Glycoprotein* ; Prognosis

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is a drug-resistant tumor. The expression of a multidrug resistant gene, P-glycoprotein (P-gp) is a major mechanism of drug resistance. The aims of our study were, firstly, to observe the expression rate of P-gp in HCC tissue obtained by percutaneous fine needle aspiration (PCNA) from stage IV HCC patients; secondly to examine the association between P-gp and chemotherapeutic response; and finally to investigate the correlation between p53 protein expression and P-gp expression. Subjects and METHODS: We studied 29 cases of stage IV HCC treated by systemic chemotherapy. Expression of P-gp and p53 were evaluated by immunohistochemical staining of HCC tissue with human monoclonal antibody, JSB-1 (Anti P-gp) and DO-7 (Anti p53), respectively. We analyzed the results of immunohistochemical staining of HCC tissues of the patients in relation to chemotherapeutic response and other clinical characteristics. RESULTS: The expression rate of P-gp was 27.6%. Partial response to anti-cancer chemotherapy was observed in 16.7% of the patients. Although we could not see a statistically significant association between P-gp expression and chemotherapeutic response, none of the responsive patients showed P-gp expression. p53 protein expression was found in 45% of the patients. There was no significant correlation between p53 protein expression and P-gp expression. CONCLUSIONS: Although the number of our study subjects was small, chemotherapy- responsive patients didn't show P-gp expression. P-gp expression might be used as a predictor of response to potentially toxic anti-cancer chemotherapy in HCC patients. Further study is warranted to confirm our results.
Biopsy, Fine-Needle ; Carcinoma, Hepatocellular* ; Drug Resistance ; Drug Therapy* ; Humans ; P-Glycoprotein*